A safety study of retinal toxicity after serial intravitreal injections of infliximab in rabbits eyes;Estudo de toxicidade retiniana após injeções intravítreas seriadas de infliximabe em olhos de coelhos

Arquivos Brasileiros de Oftalmologia

Volumn 74, Issue 5, 2011, Pages 352-356

  Rassi, Alan Ricardo ^a   Rigueiro, Moacyr Pezati ^b   Isaac, David Leonardo Cruvinel ^a   Dourado, Letícia ^b   Abud, Murilo Batista ^a   Freitas, Éricka Campos ^a   Carneiro, Luciana Barbosa ^a   De Ávila, Marcos Pereira ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animals; Antibodies, monoclonal administration dosage; Choroid diseases drug therapy; Electroretinography; Injections, intravenous; Macular degeneration; Rabbits; Retina; Retinal diseases drug therapy; Tumor necrosis factor alpha

Indexed keywords

ANTIINFLAMMATORY AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTRORETINOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; OPHTHALMOSCOPY; PATHOLOGY; RABBIT; RETINA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; INTRAVITREAL INJECTIONS; OPHTHALMOSCOPY; RABBITS; RETINA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856770408     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492011000500009     Document Type: Article

References (30)

1. Locksley RM, Killeen N, Leonardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487-501.
2. Joussen AM, Poulaki V, Le ML, Koizumi K, Janicki H, Schraemeyer U, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450-2.
3. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 1996:80(2):168-73.
4. Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nikola T, Grus F, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica. 1998;212(6):410-4.
5. Shi X, Semkova I, Müther PS, Dell S, Kociok N, Joussen AM. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res. 2006;83(6):1325-34.
6. Dick AD, Forrest JV, Liversidge J, Cope AP. The role of tumor necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617-37.
7. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, et al. Aqueous humor and serum tumor necrosis factor alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251-5.
8. Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Imununol Inflamm. 1998;6(2):111-20.
9. Fleisher LN, Ferrell JB, McGahan MC. Ocular inflammatory effects of intravitreally injected tumor necrosis factor an endotoxin. Inflammation. 1990;14(3):325-35.
10. Rosenbaum JT Howes EL Jr, Rubin RM, Samples JR. Ocular inflammatory effects of intravitreally- injected tumor necrosis factor. Am J Pathol. 1988;133(1):47-53.
11. Santos Lacomba M, Marcos Martin C, Gallardo Calera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, et al. Aqueous humor and serum tumor necrosis factor alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251-5.
12. Palexas GN, Sussman G, Welsh NH. Ocular and systemic determination of IL-1 beta and tumor necrosis factor in a patient with ocular inflammation. Scand J Immunol. 1192;11:173-5.
13. Dastgheib K, Green WR. Granulomatous reaction to Bruch́s membrane in age - related macular degeneration. Arch Ophthalmol. 1994;112(6):813-8.
14. Hutchinson AK, Grossniklaus HE, Capone A. Giant-cell reaction in surgically excised subretinal neovascular membrane. Arch Ophthalmol. 1993;111(6):734-5.
15. Killingsworth MC, Sarks JP, Sarks SH. Macrophages related to Bruch́s membrane in age related macular degeneration Eye (Lond). 1990;4(Pt 4):613-21.
16. Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40(9):1891-8.
17. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric antitumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid placebo en rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRATCT Study Group. Lancet. 2000;354(9194):1932-9.
18. Lewis JD. Anti-TNF antibodies for Crohn's disease-in pursuit of the perfect clinical trial. N Engl J Med. 2007;357(3):296-8.Comment in: N Engl J Med. 2007;357(16):1662; author reply 1662. Comment on: N Engl J Med. 2007;357(3):228-38. N Engl J Med. 2007;357(3):239-50.
19. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades- Behcet disease. Ann Intern Med. 2004;140(5):404-6.
20. Clegg DO. Treatment of ankylosing spondylitis. J Rheumatol. Suppl. 2006.78:24-31.
21. Wong M, Ziring D, Desai S, Kim S, Lin J, et al. TN-alpha blockade in human diseases: mechanisms and future directions. Clin Imunol. 2008;126(2)121-36.
22. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358(9278):295-6. Comment in: Lancet. 2001;358(9293):1644.
23. Marklomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol. 2005;139(3):537-40.
24. Sfikakis PP, Marklomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in Type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005;28(2):445-7.
25. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008;49(3):1151-6.
26. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charosis A, Agrogiannis G, Kavantzas N, et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graeffes Arch Clin Exp Ophthalmol. 2009; 247(2):273-81.
27. Hosseini H, Safael A, Khalili MR, Nowroozizadeh B, Eghtedari M, Farvardin M, et al. Intravitreal infliximab in experimental endotoxin-induced uveitis. Euro J Ophthalmol. 2009;19(5):818-23.
28. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular agerelated macular degeneration. Am J Ophthalmol. 2009;147(5):825-30. Comment in: Am J Ophthalmol. 2009;147(5):761-3.
29. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events following intravitreal infliximab (Remicade). Retina. 2010;30(1):71-80.
30. Farvadin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the reatment of sightthreatening chronic noninfectious uveitis. Retina. 2010;30(9):1530-5.